News
Life Sciences M&A Values Soar in 2011 May 14, 2012 | Press Release
Life Sciences M&A Activity Heats Up in April, says Burrill & Company May 01, 2012 | Press Release
Burrill & Company Leads $12.9 Million Series E Round In WhiteGlove Health April 16, 2012 | Press Release
See all News
Joshua Zelig
DirectorJoshua Zelig joined Burrill & Company as a Director in the Venture Group in 2011. Prior to joining the Company, Mr. Zelig was an Associate Partner at GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. In that capacity he was responsible for sourcing, evaluating, and executing investment transactions and new business opportunities. Additionally, Mr. Zelig managed the firm’s intellectual property portfolios, oversaw the company’s operations, and worked closely with portfolio companies in setting and delivering strategic objectives.
Previously, Mr. Zelig was an Equity Research associate at Morgan Stanley where he covered biotech and consumer stocks. He later worked in real estate management, acquisition, and due diligence on behalf of a number of large private real estate companies as well as public REITs.
Mr. Zelig is a graduate of Yeshiva University, Sy Syms School of Business, where he received a Bachelor of Science in Finance. He is currently a member of the board of directors of Flexible Stenting Solutions, Inc.


